Modified and Stabilized GDF Propeptides and Uses Thereof
    51.
    发明申请
    Modified and Stabilized GDF Propeptides and Uses Thereof 失效
    改良和稳定的GDF前体肽及其用途

    公开(公告)号:US20120252884A1

    公开(公告)日:2012-10-04

    申请号:US13523391

    申请日:2012-06-14

    摘要: Modified and stabilized propeptides of Growth Differentiation Factor proteins, such as GDF-8 and Bone Morphogenetic Protein-11, are disclosed. Also disclosed are methods for making and using the modified propeptides to prevent or treat human or animal disorders in which an increase in muscle tissue would be therapeutically beneficial. Such disorders include muscle or neuromuscular disorders (such as amyotrophic lateral sclerosis, muscular dystrophy, muscle atrophy, congestive obstructive pulmonary disease, muscle wasting syndrome, sarcopenia, or cachexia), metabolic diseases or disorders (such as such as type 2 diabetes, noninsulin-dependent diabetes mellitus, hyperglycemia, or obesity), adipose tissue disorders (such as obesity), and bone degenerative diseases (such as osteoporosis).

    摘要翻译: 公开了生长分化因子蛋白如GDF-8和骨形态发生蛋白-11的修饰和稳定的前肽。 还公开了制备和使用经修饰的前肽以预防或治疗其中肌肉组织增加在治疗上有益的人或动物疾病的方法。 这些疾病包括肌肉或神经肌肉疾病(如肌萎缩性侧索硬化,肌营养不良,肌肉萎缩,充血性阻塞性肺疾病,肌肉萎缩综合征,肌营养不良或恶病质),代谢疾病或病症(例如2型糖尿病, 依赖性糖尿病,高血糖或肥胖),脂肪组织障碍(如肥胖症)和骨退行性疾病(如骨质疏松症)。

    GDF3 ANTIBODIES AND RELATED METHODS
    57.
    发明申请
    GDF3 ANTIBODIES AND RELATED METHODS 有权
    GDF3抗体及相关方法

    公开(公告)号:US20120202739A1

    公开(公告)日:2012-08-09

    申请号:US13453759

    申请日:2012-04-23

    摘要: In certain aspects, the present invention provides compositions and methods for regulating body weight, in particular, for treating obesity and obesity-associate disorders. The present invention also provides methods of screening compounds that modulate activity of GDF3. The compositions and methods provided herein are also useful in treating diseases associated with abnormal activity of GDF3.

    摘要翻译: 在某些方面,本发明提供了用于调节体重的组合物和方法,特别是用于治疗肥胖症和肥胖相关疾病。 本发明还提供了筛选调节GDF3活性的化合物的方法。 本文提供的组合物和方法也可用于治疗与GDF3的异常活性相关的疾病。

    PKD Ligands and Polynucleotides Encoding PKD Ligands
    58.
    发明申请
    PKD Ligands and Polynucleotides Encoding PKD Ligands 审中-公开
    编码PKD配体的PKD配体和多核苷酸

    公开(公告)号:US20120195866A1

    公开(公告)日:2012-08-02

    申请号:US13348515

    申请日:2012-01-11

    申请人: Thomas D. REED

    发明人: Thomas D. REED

    CPC分类号: C07K14/4703 C12N9/1205

    摘要: The invention relates to kinase ligands and polyligands. In particular, the invention relates to ligands, homopolyligands, and heteropolyligands that modulate protein kinase D (PKD) activity. The ligands and polyligands are utilized as research tools or as therapeutics. The invention includes linkage of the ligands and polyligands to cellular localization signals, epitope tags and/or reporters. The invention also includes polynucleotides encoding the ligands and polyligands.

    摘要翻译: 本发明涉及激酶配体和聚合配体。 特别地,本发明涉及调节蛋白激酶D(PKD)活性的配体,均聚配体和杂多糖配体。 配体和聚合物配体被用作研究工具或治疗剂。 本发明包括配体和聚合配体与细胞定位信号,表位标签和/或记者的连接。 本发明还包括编码配体和聚合配体的多核苷酸。

    SCREENING METHOD UTILIZING THALIDOMIDE-TARGETING FACTOR
    60.
    发明申请
    SCREENING METHOD UTILIZING THALIDOMIDE-TARGETING FACTOR 有权
    筛选方法利用半胱氨酸靶向因子

    公开(公告)号:US20120192297A1

    公开(公告)日:2012-07-26

    申请号:US13498067

    申请日:2010-10-18

    CPC分类号: G01N33/566 G01N2500/04

    摘要: With an aim to provide means for developing a compound devoid of teratogenicity but retaining beneficial actions, a screening method for a non-teratogenic substance comprising bringing a test substance into contact with cereblon or a fragment of cereblon, evaluating the bindability of the test substance with cereblon or the fragment of cereblon, and selecting a test substance that does not bind to cereblon or the fragment of cereblon or a test substance exhibiting lower bindability with cereblon or the fragment of cereblon than does thalidomide is provided.

    摘要翻译: 目的是提供开发不具有致畸性但保留有益作用的化合物的方法,用于非致畸物质的筛选方法,包括使测试物质与大脑或脑片的片段接触,评估测试物质与 提供了与沙门氏菌相比,不能结合到脑部或与本发明的化合物相比较的表现出与巧克力片或巧克力片相比具有较低粘合性的测试物质的测试物质。